greeksoup/ stock research
Stock research / United States / Funds / Fairmount Funds Management LLC

Fairmount Funds Management LLC

CIK 1802528 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Fairmount Funds Management LLC reported 12 US-listed holdings worth $1.51 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Oruka Therapeutics Inc. (23.3%), Dianthus Therapeutics Inc. (16.3%) and Galecto Inc. (15.0%). Against the quarter before, it opened 1 position, added to 1, trimmed 0 and sold out of 1.

Reported holdings$1.51B+9.3% on Q1 2026
Positions12as many as Q1 2026
The largest ten97.6%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedAdded toHeld
ORKA23.3%DNTH16.3%DMRA15.0%COGT14.1%JBIO6.7%ELVN6.2%VRDN6.2%ZBIO4.0%CBIO3.3%APGE2.6%FTH1.2%IKT1.2%

The 12 largest of its 12 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $1.23 billion in 15 positions$1.23BQ3 24Q4 2024: $1.01 billion in 17 positions$1.01BQ4 24Q1 2025: $644.6 million in 15 positions$645MQ1 25Q2 2025: $771.9 million in 17 positions$772MQ2 25Q3 2025: $1.11 billion in 17 positions$1.11BQ3 25Q4 2025: $1.31 billion in 13 positions$1.31BQ4 25Q1 2026: $1.38 billion in 12 positions$1.38BQ1 26Q2 2026: $1.51 billion in 12 positions$1.51BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 1Added 1Held 10Sold out 1
Opened: 1Added: 1Held: 10Sold out: 1

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 1

  1. Sensei Biotherapeutics Inc. FTH$18.1 million

Added to 1

  1. Viridian Therapeutics Inc. VRDN+1.2 million shares · +30%

Sold out of 1

  1. Spyre Therapeutics Inc. SYRE$202.7 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Oruka Therapeutics Inc. ORKA3,705,262$352.6 million23.31%no change
Dianthus Therapeutics Inc. DNTH2,537,191$247.3 million16.35%no change
Galecto Inc. DMRA8,713,000$226.6 million14.98%no change
Cogent Biosciences Inc. COGT5,503,418$213.0 million14.08%no change
Jade Biosciences Inc. JBIO4,553,494$101.2 million6.69%no change
Enliven Therapeutics Inc. ELVN1,855,644$94.2 million6.22%no change
Viridian Therapeutics Inc. VRDN5,090,928$93.5 million6.18%+1,176,470
Zenas Biopharma Inc. ZBIO2,359,025$59.9 million3.96%no change
Crescent Biopharma Inc. CBIO2,747,866$49.5 million3.27%no change
Apogee Therapeutics Inc. APGE298,647$39.6 million2.62%no change
Sensei Biotherapeutics Inc. FTH722,020$18.1 million1.19%new
Inhibikase Therapeutics Inc. IKT8,625,000$17.5 million1.16%no change
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 1 it sold out of are in the box above.